Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Merck KGaA's gross profit for the
three
months ended in Mar. 2026 was CHF2,790 Mil. Merck KGaA's gross profit for the trailing twelve months (TTM) ended in Mar. 2026 was CHF11,394 Mil.
Gross Margin % is calculated as gross profit divided by its revenue. Merck KGaA's gross profit for the
three
months ended in Mar. 2026 was CHF2,790 Mil. Merck KGaA's Revenue for the
three
months ended in Mar. 2026 was CHF4,673 Mil. Therefore, Merck KGaA's Gross Margin % for the quarter that ended in Mar. 2026 was 59.70%.
Merck KGaA had a gross margin of 59.70% for the quarter that ended in Mar. 2026 => Durable competitive advantage
During the past 13 years, the highestGross Margin % of Merck KGaA was 65.38%. The lowest was 58.51%. And the median was 62.16%.
Warning Sign:
Merck KGaA gross margin has been in long-term decline. The average rate of decline per year is -1.2%.
Merck KGaA (XSWX:MER) Gross Profit Explanation
Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.
Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %
1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key
Merck KGaA had a gross margin of 59.70% for the quarter that ended in Mar. 2026 => Durable competitive advantage
Merck KGaA Gross Profit Related Terms
Merck KGaA Gross Profit Historical Data
* Premium members only.
The historical data trend for Merck KGaA's Gross Profit can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
XSWX:MER vs ZTS, UTHR, VTRS: Gross Profit Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Merck KGaA's Gross Profit, along with its competitors' market caps and Gross Profit data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Merck KGaA Gross Profit vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Merck KGaA's Gross Profit distribution charts can be found below:
* The bar in red indicates where Merck KGaA's Gross Profit falls into.
Gross Profit for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was CHF11,394 Mil.
Gross Profit is the numerator in the calculation of Gross Margin.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.
Merck KGaA (XSWX:MER) has a Gross Profit of CHF11,394 Mil as of Mar. 2026. Gross Profit equals net sales less total cost of goods sold. View historical data on Merck KGaA and its competitors.
Is Merck KGaA's Gross Profit too high?
Merck KGaA's current Gross Profit is CHF11,394 Mil. Overall, Merck KGaA has a GF Score™ of 84/100, reflecting its overall financial health beyond just this single metric.
How does Merck KGaA's Gross Profit compare to ZTS and UTHR?
Merck KGaA's Gross Profit of CHF11,394 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Gross Profit for a Drug Manufacturers company?
A good Gross Profit depends on the Drug Manufacturers industry context. However, Gross Profit should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Gross Profit mean?
A high Gross Profit can signal that a stock is expensive relative to its fundamentals. Gross Profit equals net sales less total cost of goods sold. View historical data on Merck KGaA and its competitors. Merck KGaA's current Gross Profit is CHF11,394 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Merck KGaA stock overvalued right now?
Merck KGaA (XSWX:MER) has a current Gross Profit of CHF11,394 Mil. The stock's GF Value™ is CHF129.05, compared to a current price of CHF127.50 — trading 1.2% below its estimated fair value. The current Gross Profit is CHF11,394 Mil. Merck KGaA's overall GF Score™ is 84/100 with 10 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Gross Profit calculated?
Gross Profit is calculated from a company's financial statements. For Merck KGaA (XSWX:MER), the current Gross Profit is CHF11,394 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Merck KGaA (XSWX:MER) Overvalued in 2026?
Based on GuruFocus' analysis, Merck KGaA stock appears to be undervalued.
The current stock price of CHF127.50 is trading 1.2% below its estimated GF Value™ of CHF129.05.
Key valuation signals for XSWX:MER:
Gross Profit: CHF11,394 Mil
GF Value™: CHF129.05 vs. price of CHF127.50 (1.2% below fair value)
No single metric tells the full story. See the XSWX:MER stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Merck KGaA operates in three main segments: Life Science, Electronics, and Healthcare. The Life Science segment provides laboratory consumables and instruments to researchers in academia and applied fields, including the biopharmaceutical industry. The Electronics segment offers specialty materials to manufacture a variety of products, such as semiconductors and flat-screen televisions. In the healthcare segment, Merck develops, manufactures, and sells branded pharmaceuticals with significant therapeutic concentrations in oncology, multiple sclerosis, and fertility. In 1995, the E. Merck KG family publicly sold part of the company, resulting in the current 30% public ownership of the firm.
84GF Score
Get the complete analysis for XSWX:MER
Gross Profit is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XSWX:MER has been successfully added to your 
